114 related articles for article (PubMed ID: 28913538)
1. Differences in cisplatin distribution in sensitive and resistant ovarian cancer cells: a TEM/NanoSIMS study.
Lee RFS; Riedel T; Escrig S; Maclachlan C; Knott GW; Davey CA; Johnsson K; Meibom A; Dyson PJ
Metallomics; 2017 Oct; 9(10):1413-1420. PubMed ID: 28913538
[TBL] [Abstract][Full Text] [Related]
2. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
Corte-Rodríguez M; Espina M; Sierra LM; Blanco E; Ames T; Montes-Bayón M; Sanz-Medel A
Biochem Pharmacol; 2015 Nov; 98(1):69-77. PubMed ID: 26352094
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Evaluation of Cisplatin Uptake in Sensitive and Resistant Individual Cells by Single-Cell ICP-MS (SC-ICP-MS).
Corte Rodríguez M; Álvarez-Fernández García R; Blanco E; Bettmer J; Montes-Bayón M
Anal Chem; 2017 Nov; 89(21):11491-11497. PubMed ID: 29023104
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
Cheng G; Li Y; Tian F
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
[TBL] [Abstract][Full Text] [Related]
6. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Jaehde U
J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
Parekh H; Simpkins H
Cancer Chemother Pharmacol; 1996; 37(5):457-62. PubMed ID: 8599869
[TBL] [Abstract][Full Text] [Related]
8. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells.
Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H
Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682
[TBL] [Abstract][Full Text] [Related]
10. Effect of hyperthermia on cisplatin sensitivity in human glioma and ovarian carcinoma cell lines resistant and sensitive to cisplatin treatment.
Raaphorst GP; Chabot P; Doja S; Wilkins D; Stewart D; Ng CE
Int J Hyperthermia; 1996; 12(2):211-22. PubMed ID: 8926390
[TBL] [Abstract][Full Text] [Related]
11. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
12. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
Nguyen EV; Huhtinen K; Goo YA; Kaipio K; Andersson N; Rantanen V; Hynninen J; Lahesmaa R; Carpen O; Goodlett DR
Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells.
Cadoni E; Vanhara P; Valletta E; Pinna E; Vascellari S; Caddeo G; Isaia F; Pani A; Havel J; Pivetta T
Rapid Commun Mass Spectrom; 2019 Jan; 33(1):97-106. PubMed ID: 30376198
[TBL] [Abstract][Full Text] [Related]
14. Analytical strategies to study the formation and drug delivery capabilities of ferritin-encapsulated cisplatin in sensitive and resistant cell models.
Turiel-Fernández D; Blanco-González E; Corte-Rodríguez M; Bettmer J; Montes-Bayón M
Anal Bioanal Chem; 2020 Sep; 412(24):6319-6327. PubMed ID: 32185440
[TBL] [Abstract][Full Text] [Related]
15. Chemical bioimaging for the subcellular localization of trace elements by high contrast TEM, TEM/X-EDS, and NanoSIMS.
Penen F; Malherbe J; Isaure MP; Dobritzsch D; Bertalan I; Gontier E; Le Coustumer P; Schaumlöffel D
J Trace Elem Med Biol; 2016 Sep; 37():62-68. PubMed ID: 27288221
[TBL] [Abstract][Full Text] [Related]
16. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of small-molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells.
Yellepeddi VK; Vangara KK; Kumar A; Palakurthi S
Anticancer Res; 2012 Sep; 32(9):3651-8. PubMed ID: 22993302
[TBL] [Abstract][Full Text] [Related]
19. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
20. Quantitative differences in protein expression between cisplatin sensitive C0C1 ovarian carcinoma cells and cisplatin resistant C0C1/DDP cells.
Wang HX; Sun W; Li HL; Zhang WY
Chin Med J (Engl); 2009 Apr; 122(7):865-9. PubMed ID: 19493403
[No Abstract] [Full Text] [Related]
[Next] [New Search]